Publications
Dr. Ashwani Mehta is a renowned Non-invasive & Invasive Cardiologist in New Delhi. His special interest lies in Stem Cells, Preventive Cardiology and Heart Transplant Programs. His illustrious career involves attending to the Honorable President of India in 2001 at SGRH & Ms Sonia Gandhi in 2008. Apart from working as a consultant cardiologist, Dr. Mehta is actively involved in teaching, public awareness lectures and community based preventative & charitable programs which includes organizing free clinic for poor patients at Sir Ganga Ram Hospital.
• Conducted 35 National & International clinical trials as Principal investigator & Co-investigator Phase – II, III & IV trails GCP Certified. Some of the trials have changed the medical practices and guidelines like PARADIGM HF, RELY , PARAGON , etc
• Epidemiological study done to look at incidence of Metabolic Syndrome in Indian Urban population.
• Epidemological study undertaken to look at incidence of NIDDM and CAD Urban Population .
• Study of risk factors of CAD in the young patients presenting with myocardial infarction .
• Risk factor evalauation in females having MI as presentation at a young age
LATEST COMPLETED AND ONGOING TRIALS
• A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).EMPEROR-PRESERVED
• A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patient with chronic Heart Failure with reserved ejection fraction (HFrEF).EMPEROR –REDUCED
• Ultimaster: Prospective, single arm multicenter, observational Registry to further validate Safety and Efficacy of the ultimaster DES in Real world patient
• A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction
• A multi-Center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to Ramipril on Morbidity and Mortality in High Risk Patient following an Acute Myocardial Infraction.
• A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease
• A prospective, multicenter, randomized, open label, active controlled study to assess effect of
• Remogliflozin on biomarkers of heart failure compared to Empagliflozin in patients of type 2 diabetes mellitus with chronic heart failure (REMIT-HF)
• Protocol number: (1245‐0202)‐ EMPACT‐MI: A streamlined, multicenter, randomized, parallel group, double blind placebo controlled,superiority trial to evaluate the effect of EMPAgliflozin on hospitalization for heart failure and mortality in patients with acute myocardial infarction
ONGOING MAJOR INTERNATIONAL TRIALS AS PRINCIPAL INVESTIGATOR
• HORIZON STUDY – Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD
• EMPACT MI – EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
• LIB- TRIALS - Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction
• VICTORION-INITIATE- A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy
Contributed to various chapters in cardiology text books
1. Contributed to various Cardiology Books including a chapter on "Management of Acute Coronary Syndrome" as the co aurthor in API text took of Medicine
2. Contributed chapter- An Algorhythmic approach to treatment of Arrythmia in children.
3. Emergencies in Infectious diseases: from head to toe. Editors Nancy Misri Khardori, Chand Wattal. 1st ed 2010 Byword Books, New Delhi.
RECENT IMPORTANT PUBLICATIONS:
1. Bempedoic Acid for Lipid Management in the Indian Population: An Expert Opinion , Article,February 2023, Cureus , Jagdish Hiremath, J C Mohan, A Mehta. DOI:10.7759/cureus.35395
2. Effect of Remogliflozin on biomarkers compared to empagliflozin in patients of Type 2 Diabetes Mellitus with chronic heart failure. J Am Coll Cardiol. 2023 Mar, 81 (8_Supplement) 316. Sengupta S, Balagopalan J, Mehta A, et al.https://doi.org/10.1016/S0735-1097(23)00760-X
3. Short-term clinical and echocardiographic outcomes after use of polytetrafluoroethylene bicuspid pulmonary valve during the repair of tetralogy of Fallot. Wankhade PR, Aggarwal N, Joshi RK, Agarwal M, Joshi R, Mehta A, Kar S. Ann Pediatr Cardiol. 2019 Jan-Apr;12(1):25-31. doi: 10.4103/apc.APC_51_18. PMID: 30745766 Free PMC Article Select item 30595326
4. To study the effect of high dose Atorvastatin 40mg versus 80mg in patients with dyslipidemia. Agrawal D, Manchanda SC, Sawhney JPS, Kandpal B, Jain R, Mehta A, Mohanty A, Passey R, Makhija A, Sharma MK. Indian Heart J. 2018 Dec;70 Suppl 3:S8-S12. doi: 10.1016/j.ihj.2018.01.034. Epub 2018 Jan 31. PMID: 30595326 Free Article, Select item 30595239
5. Anemia profile in patients with congestive heart failure a hospital based observational study. Arora H, Sawhney JPS, Mehta A, Mohanty A. Indian Heart J. 2018 Dec;70 Suppl 3:S101-S104. doi: 10.1016/j.ihj.2018.06.017. Epub 2018 Jun 30.PMID: 30595239 Free Article,Select item 30393992
6. Prognostic significance, angiographic characteristics and impact of antithrombotic and anticoagulant therapy on outcomes in high versus low grade coronary artery ectasia: A long-term follow-up study.Gunasekaran P, Stanojevic D, Drees T, Fritzlen J, Haghnegahdar M, McCullough M, Barua R, Mehta A, Hockstad E, Wiley M, Earnest M, Tadros P, Genton R, Gupta K. Catheter Cardiovasc Interv. 2018 Nov 4. doi: 10.1002/ccd.27929. [Epub ahead of print] PMID: 30393992 ,Select item 30347952
7. Prevalence of Hyperuricemia in Indian Subjects attending Hyperuricemia Screening Programs-A Retrospective Study.Billa G, Dargad R, Mehta A. J Assoc Physicians India. 2018 Apr;66(4):43-6. PMID: 30347952, Select item 28845751
8. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.PMID: 28845751 Free Article ,Select item 28756420
9. Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Stenosis.Lippmann M, Patel J, Kvapil J, Westover D, Pierpoline M, Tadros P, Wiley M, Zorn G 3rd, Muehlebach G, Mehta A, Hockstad E, Earnest M, Gupta K. J Invasive Cardiol. 2017 Aug;29(8):271-275.PMID: 28756420 Free Article ,Select item 28081827
10. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL; CHAMPION Investigators. J Am Coll Cardiol. 2017 Jan 17;69(2):176-185. doi: 10.1016/j.jacc.2016.10.055. PMID: 28081827 Free Article,Select item 27931543
11. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2. Shah CP, Shah BP, Dani SI, Channa BB, Lakshmanan SS, Krishnamani NC, Mehta A, Moorthy P.Indian Heart J. 2016 Nov - Dec;68(6):766-771. doi: 10.1016/j.ihj.2016.09.002. Epub 2016 Sep 21.PMID: 27931543 Free PMC Article, Select item 27315577
12. Indian Recommendations on Antithrombotic Management for Chronic Coronary Syndrome: An Expert Consensus Delphi Study. Heart, Lung and Circulation. 31. S34. 10.1016/j.hlc.2022.05.033 https://doi.org/10.1016/j.hlc.2022.05.033
13. Clinical characteristics of patients with Heart failure with improved ejection fraction.Article ,November 2022 ,Indian Heart Journal ,Ashwani Mehta , Gaurav Yadav , J.P.s. Sawhney
14. 90th EAS Congess ,May 22-25,2022 Milan ,Italy Achieving the LDL-C Goal <55mg/dl in Indian Patients of Acute Coronary Syndrome with High Intensity Statin
15. 90th EAS Congess ,May 22-25,2022 Milan ,Italy Achieving the LDL-C Goal <55mg/dl in Indian Patients of Acute Coronary Syndrome with High Intensity Statin
16. Improving the ACS Triage—Using High Sensitivity TroponinI and Co peptin for Early ‘Rule-Out’ of AMI ,January 2022,Indian Journal of Clinical Biochemistry. https://doi.org/10.1007/s12291-021-01015-7
17. American College of Cardiology 2022 - Abstract, "A Systemic metanalysis and review of the evidence from the published case Reports and Vaccine adverse events reporting systems for Myocarditis following Covid 19 Vaccination" at the ACC 71st Annual Scientific Session, April 2-4, 2022 in Washington, D.C. It has also been published in JACC , 2065 JACC March 8, 2022, Volume 79, Issue 9,suppl A
18. Short term clinical and echocardiographic outcomes after use of polytetrafluoroethylene (PTFE) bicuspid pulmonary valve during the repair of Tetralogy of Fallot, Year : Annals of Pediatric Cardiology 2019 | Volume : 12 | Issue : 1 | Page : 25-31 https://doi.org/10.4103%2Fapc.APC_51_18
19. Short term clinical and echocardiographic outcomes after use of polytetrafluroethylene (ptfe) bicuspid pulmonary valve during primary repair of tetralogy of fallot J P S Sawhney , Ashwani Mehta, Prashant Wankhede, Raja Joshi, Neeraj Aggarwal, Mridul Agarwal, Presentation in Indian Heart Journal 69(S2):S8 · November 2017- 2018
20. Efficacy and safety of the intensive dose of rosuvastatin 40 mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2, INDIAN HEART JOURNAL 68 9 2016), 766-771. Ashwani Mehta, Chetan P Shah, Bhaskar P Shah, Sameer I Dani, B B Channa, S S Lakshmanan, N C Krishnamani, P Moorthy. https://doi.org/10.4103%2Fapc.APC_51_18
21. Wadhwa ‘Rosuvastatin in Ischemic Stroke: Systematic Review of the Ongoing Clinical Trials’. Presented at 10th World Stroke Congress, WSC 2016, Hyderabad, India, 26- 29 October, 2016. Ashwani Mehta , Puneet Agarwal , CS Agarwal , Jaideep Bansal , Jamshed Dalal , Sadanand Shetty , Sundeep Mishra , Navneet.
22. Anemia and Iron deficiency in Indian patients with congestive heart failure JPS Sawhney, Ashwani Mehta, Himanshu Arora, Manish Sharma, Bhuwanesh Kandpal, Arun Mohanty,
